Abstract:Long-chain fatty acids (LCFAs) are one of the main energy-supplying substances in the body. LCFAs with different lengths and saturations may have contrasting biological effects that exacerbate or alleviate progress against a variety of systemic disorders of lipid metabolism in organisms. Nonalcoholic fatty liver disease is characterized by chronic inflammation and steatosis, mainly caused by the ectopic accumulation of lipids in the liver, especially LCFAs. CD36 is a scavenger receptor that recognizes and mediates the transmembrane absorption of LCFAs and is expressed in a variety of cells throughout the body. In previous studies, our group found that 7-ketocholesteryl-9-carboxynonanoate (oxLig-1) has the biological effect of targeting CD36 to inhibit oxidized low-density lipoprotein lipotoxicity-induced lipid metabolism disorder; it has an ω-carboxyl physiologically active center and is structurally similar to LCFAs. However, the biological mechanism of oxLig-1 binding to CD36 and competing for binding to different types of LCFAs is still not clear. In this study, molecular docking and molecular dynamics simulation were utilized to simulate and analyze the binding activity between oxLig-1 and different types of LCFAs to CD36 and confirmed by the enzyme-linked immunosorbent assay (ELISA) method. Absorption, distribution, metabolism, excretion, and toxicity (ADMET) platform was applied to predict the drug-forming properties of oxLig-1, and HepG2 cells model of oleic acid and nonalcoholic fatty liver disease (NAFLD) model mice were validated to verify the biological protection of oxLig-1 on lipid lowering. The results showed that there was a co-binding site of LCFAs and oxLig-1 on CD36, and the binding driving forces were mainly hydrogen bonding and hydrophobic interactions. The binding abilities of polyunsaturated LCFAs, oxLig-1, monounsaturated LCFAs, and saturated LCFAs to CD36 showed a decreasing trend in this order. There was a similar decreasing trend in the stability of the molecular dynamics simulation. ELISA results similarly confirmed that the binding activity of oxLig-1 to CD36 was significantly higher than that of typical monounsaturated and saturated LCFAs. ADMET prediction results indicated that oxLig-1 had a good drug-forming property. HepG2 cells model of oleic acid and NAFLD model mice study results demonstrated the favorable lipid-lowering biological effects of oxLig-1. Therefore, oxLig-1 may have a protective effect by targeting CD36 to inhibit the excessive influx and deposition of lipotoxicity monounsaturated LCFAs and saturated LCFAs in hepatocytes.

Dynamic AFM detection of the oxidation-induced changes in size, stiffness, and stickiness of low-density lipoprotein

Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis

Intracellular-free calcium dynamics and F-actin alteration in the formation of macrophage foam cells.

Effects of enzymes on elastic modulus of low-density lipoproteins were investigated using atomic force microscopy

Dynamic determination of Ox-LDL-induced oxidative/nitrosative stress in single macrophage by using fluorescent probes.

Dietary Sterols and Sterol Oxidation Products on Atherosclerosis: an Insight Provided by Liver Proteomic and Lipidomic.

Mechanisms of Oxidized LDL-Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosis

Oxidation of low density lipoprotein leads to particle aggregation and altered macrophage recognition

Fluorescent probe-mediated labeling and real-time tracking of lipid droplet dynamics in foam cells formation

Effects of peripheral administration of recombinant human interleukin-1 beta on feeding behavior of the rat.

Natural products: The role and mechanism in low‐density lipoprotein oxidation and atherosclerosis

Effect of LDL Extracted from Human Plasma on Membrane Stiffness in Living Endothelial Cells and Macrophages via Scanning Ion Conductance Microscopy

Coherent control of low loss surface polaritons.

Identification of a Novel Series of Anti-Inflammatory and Anti-Oxidative Phospholipid Oxidation Products Containing the Cyclopentenone Moiety in Vitro and in Vivo: Implication in Atherosclerosis

Analysis and Quantification of Oxidized Low-Density Lipoprotein-Induced Lipid Droplets in Macrophages Through High-Content Screening: Application for Antiatherogenic Drugs Discovery

Molecular Drug Simulation and Experimental Validation of the CD36 Receptor Competitively Binding to Long-Chain Fatty Acids by 7-Ketocholesteryl-9-carboxynonanoate

Impaired lipophagy in endothelial cells with prolonged exposure to oxidized low‐density lipoprotein

Oxidized Low‐Density Lipoprotein (Ox‐LDL)‐Triggered Double‐Lock Probe for Spatiotemporal Lipoprotein Oxidation and Atherosclerotic Plaque Imaging

Targeting structural flexibility in low density lipoprotein by integrating cryo-electron microscopy and high-speed atomic force microscopy

Development of ELISA for oxidized,malondialdehyde-modified LDL and clinical value

The synergistic mechanisms of oxidized phospholipids and lipoprotein-associated phospholipase A2 associated with Lp ( a ) in promoting atherosclerosis